Evolving Landscape in Critical Care Medicine: Cellular Therapy-Related Toxicity

Concurrent Session Moderator(s)

• 

  Prabalini Rajendram, MD,

  Associate Program Director, Critical Care Medicine Fellowship
  n/a
  New York, NY

  Disclosure(s): No relevant financial relationship(s) to disclose.
• 

  Stephen Pastores, MD, MACP, FCCP

  Program Director, Critical Care Medicine
  Memorial Sloan Kettering Cancer Center
  New York, NY

  Disclosure(s): Abbvie: Advisory Board (Terminated)

Cancer cellular and immunotherapy using T cells to eliminate tumors has become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Over the past decade, development of immune effector cell (IEC)/adoptive cell therapy (ACT) has improved patient outcomes and is usually well tolerated but can cause significant adverse reactions necessitating ICU management. Similar to chimeric antigen receptor T cell (CAR-T) therapy, emerging ACTs such as T-cell receptor therapies and tumor-infiltrating lymphocytes can also cause serious toxicities that can be life-threatening if not diagnosed and treated early; therefore all ICU clinicians should recognize the symptoms and know how to apply management strategies.

Presentations:

• Update on FDA CAR-T Products and Toxicity Management Guidelines
  

  Concurrent Session Faculty: Anne Rain Brown, PharmD, BCCCP, FCCM – University of Texas MD Anderson Center
• Emerging Cellular Therapies and Associated Toxicity: What's Different From CAR-T Therapy?
  

  Concurrent Session Faculty: Colleen McEvoy, MD, – Washington University
• Recognition and Management of HLH in the Context of Cellular Therapy
  

  Concurrent Session Faculty: Matthew Hensley, MD, MPH, – UPMC Shadyside
• Update on Cost and ICU Resource Utilization for Administration of Cellular Therapy: A Review of Current Data
  

  Concurrent Session Faculty: Cristina Gutierrez, MD – University of Texas MD Anderson Cancer Center